Key Highlights
- Nura Bio closes $140M Series A financing to support clinical development.
- Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success of NB-4746.
- NB-4746 is a brain-penetrant SARM1 inhibitor with potential neuroprotective benefits.
- Phase 1 trial results show NB-4746 was well-tolerated and achieved target plasma exposure.
Source: Business Wire
Notable Quotes
- “Under Shilpa’s leadership, Nura Bio has successfully transitioned to a clinical-stage organization, making remarkable progress in identifying ways to translate complex biology into potential therapies.” — Tim Kutzkey, Ph.D., Managing Partner at The Column Group
- “I look forward to leading the company through this next phase as we prepare to test the SARM1 hypothesis in a patient population in 2025.” — Shilpa Sambashivan, Ph.D., CEO at Nura Bio
SoHC's Take
The successful closing of over $140M in Series A financing for Nura Bio underscores the increasing investor confidence in the company’s neuroprotective research and therapeutic pipeline. With NB-4746 progressing successfully through Phase 1 trials, Nura Bio is well-positioned to address significant unmet needs in the treatment of neurological diseases. Shilpa Sambashivan’s appointment as CEO is a strategic move, leveraging her deep scientific expertise and leadership to guide the company toward achieving its ambitious clinical milestones in the coming years.
Heading
Episode Details: Dental Financial Solutions Join us on this week's episode of our new Dental focused show, hosted by Jared ...
Key Highlights $11.5M Series A funding led by Construct Capital with participation from GC 1 Capital, One Way Ventures, and 2048 ...
Key Highlights Tabia Health integrates American Heart Association CarePlans into its AI-powered healthcare orchestration platform. Joins the American Heart Association Center ...
Key Highlights Heyward Donigan appointed CEO of Health Network One beginning January 1, 2025. Luis Mosquera transitions to Executive Chairman, focusing on strategic growth. Donigan ...
Key Highlights $31.5 million Series B funding led by Oak HC/FT, backed by Y Combinator, Reach Capital, and more. Programs for ...
Key Highlights Patterson Dental extends partnership with PDS Health until 2027. Agreement secures Patterson as PDS Health’s premier distributor for technology, equipment, and services. Over ...
